Research Topics
| G Varuni KondaguntaSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Semin Urol Oncol 20:239-43. 2002..A prospective trial of 2 cycles of etoposide plus cisplatin adjuvant chemotherapy for patients with pN2 tumors showed that this regimen was highly effective in achieving relapse-free survival...- Chemotherapy for advanced germ cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:5493-502. 2006..This review summarizes the prognostic criteria on which treatment decisions may be based, and outlines the current treatment approaches... - Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:85-90. 2007..This prospective trial followed a similarly designed report of TICE, which used a different means of carboplatin dosing... - Adjuvant chemotherapy for stage II nonseminomatous germ cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Urol Clin North Am 34:179-85; abstract ix. 2007..In contrast, patients who have high-volume nodal involvement at RPLND have a relapse rate of 50% to 90% with surveillance alone, and adjuvant chemotherapy is the preferable option in this group... - Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 23:9290-4. 2005.... - Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumorsG Varuni Kondagunta
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 23:6549-55. 2005..The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed testicular germ cell tumors (GCTs)... - Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapyG Varuni Kondagunta
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:464-7. 2004.... - Treatment outcome for metastatic papillary renal cell carcinoma patientsEllen A Ronnen
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 107:2617-21. 2006..Further understanding of the genetics and molecular biology and subtypes involved may provide the basis for more effective agents. Treatment with targeted therapies or other experimental agents is warranted... - Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapyEllen A Ronnen
Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 23:6999-7004. 2005..Chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by surgery may be effective in patients with late-relapse GCT who are not considered candidates for primary surgery... 
Clinical outcome and predictors of survival in late relapse of germ cell tumorDavid S Sharp
Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
J Clin Oncol 26:5524-9. 2008..Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival...- Phase II trial of lenalidomide in patients with metastatic renal cell carcinomaPremal H Patel
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 26:273-6. 2008..Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial... - A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaEllen A Ronnen
From the Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Invest New Drugs 24:543-6. 2006..Six of the 20 patients required dose reduction. At the dose and schedule used in this trial, 17-AAG did not achieve objective response in the treatment of clear cell or papillary renal cell carcinoma patients... - Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinomaDarren R Feldman
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Genitourin Cancer 6:25-30. 2008..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)... - Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumorsDarren R Feldman
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Invest New Drugs 25:487-90. 2007..For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT... - Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumorsScott E Eggener
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 109:528-35. 2007..The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT... - Long-term response with sunitinib for metastatic renal cell carcinomaEllen A Ronnen
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 68:672.e19-20. 2006..This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma... - Phase II trial of bortezomib for patients with advanced renal cell carcinomaG Varuni Kondagunta
Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:3720-5. 2004..Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered... - Recommendations of follow-up after treatment of germ cell tumorsG Varuni Kondagunta
Department of Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
Semin Oncol 30:382-9. 2003..Optimal means of imaging and frequency of physician visits and serum marker level measurements need to be further addressed... - Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profilingJames E Korkola
Department of Cell Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:1264-8; discussion 1268. 2007..We identified differentially expressed genes associated with response to pegylated interferon-alpha treatment in patients with renal cell carcinoma... - Management of difficult germ-cell tumorsChristie J Moore
Department of Medicine, Division of Hematology/Oncology, Oregon Health and Science University, Portland, Oregon, USA
Oncology (Williston Park) 20:1565-70, 1575; discussion 1575-6. 2006..In a series of case presentations, we review the evaluation and management of patients with persistent elevation of serum tumor markers and postchemotherapy residual radiographic abnormalities... - Medullary renal cell carcinoma and response to therapy with bortezomibEllen A Ronnen
J Clin Oncol 24:e14. 2006 
Expression of prostate-specific membrane antigen in renal cortical tumorsHikmat A Al-Ahmadie
Department of Pathology, University of Chicago, Chicago, IL, USA
Mod Pathol 21:727-32. 2008....